Literature DB >> 9154768

High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura.

C Law1, M Marcaccio, P Tam, N Heddle, J G Kelton.   

Abstract

BACKGROUND: High-dose intravenous immune globulin produces a temporary rise in the platelet count in patients with idiopathic thrombocytopenic purpura. Splenectomy may also be effective, but it is not possible to predict which patients will have a good response. We hypothesized that the response to intravenous immune globulin predicts the response to splenectomy.
METHODS: We studied retrospectively 30 patients with idiopathic thrombocytopenic purpura who had first been treated with immune globulin and then undergone splenectomy. The responses to the two treatments were classified on the basis of the platelet count as poor (<50,000 per cubic millimeter), good (50,000 to 150,000 per cubic millimeter), or excellent (>150,000 per cubic millimeter).
RESULTS: All nine patients who had poor responses to intravenous immune globulin also had poor responses to splenectomy at one year. Of the 21 patients with good or excellent responses to intravenous immune globulin, 19 had good or excellent responses to splenectomy.
CONCLUSIONS: Patients with idiopathic thrombocytopenic purpura who have good or excellent responses to intravenous immune globulin are likely to have good or excellent responses to splenectomy, whereas patients who have poor responses to intravenous immune globulin are unlikely to have good or excellent responses to splenectomy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9154768     DOI: 10.1056/NEJM199705223362104

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  10 in total

1.  Successful treatment of immune thrombocytopenic purpura (ITP) with splenectomy.

Authors:  P Ortega Deballon; M T Alonso García; M Moreno Azcoita
Journal:  World J Surg       Date:  2001-02       Impact factor: 3.352

2.  Predictors of response after laparoscopic splenectomy for immune thrombocytopenic purpura.

Authors:  N Katkhouda; S W Grant; E Mavor; M H Friedlander; R V Lord; K Achanta; R Essani; R Mason
Journal:  Surg Endosc       Date:  2001-02-06       Impact factor: 4.584

Review 3.  The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.

Authors:  Alina Sesarman; Gestur Vidarsson; Cassian Sitaru
Journal:  Cell Mol Life Sci       Date:  2010-03-09       Impact factor: 9.261

4.  Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia.

Authors:  Rachael F Grace; Carolyn M Bennett; A Kim Ritchey; Michael Jeng; Courtney D Thornburg; Michele P Lambert; Michelle Neier; Michael Recht; Manjusha Kumar; Victor Blanchette; Robert J Klaassen; George R Buchanan; Margaret Heisel Kurth; Diane J Nugent; Alexis A Thompson; Kimo Stine; Leslie A Kalish; Ellis J Neufeld
Journal:  Pediatr Blood Cancer       Date:  2011-06-14       Impact factor: 3.167

5.  A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding.

Authors:  Rosarin Sruamsiri; Piyameth Dilokthornsakul; Chayanin Pratoomsoot; Nathorn Chaiyakunapruk
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

Review 6.  Splenectomy for immune thrombocytopenia: down but not out.

Authors:  Shruti Chaturvedi; Donald M Arnold; Keith R McCrae
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

7.  [Splenectomy for thrombocytopenic purpura. Retrospective analysis of the postoperative course].

Authors:  K Beseoglu; U Germing; W Gross-Weege
Journal:  Chirurg       Date:  2005-08       Impact factor: 0.955

8.  [Idiopathic thrombocytopenic purpura (Werlhof disease) and differential diagnosis from other thrombocytopenic hemorrhagic diatheses].

Authors:  Kim B Luley; Thomas Wagner
Journal:  Med Klin (Munich)       Date:  2009-05-15

9.  Hematological long-term results of laparoscopic splenectomy for patients with idiopathic thrombocytopenic purpura: a case control study.

Authors:  F J Berends; N Schep; M A Cuesta; H J Bonjer; M C Kappers-Klunne; P Huijgens; G Kazemier
Journal:  Surg Endosc       Date:  2004-02-02       Impact factor: 4.584

10.  Indium-111 OXINE scintigram in children with cITP: clinical usefulness for indicating splenectomy.

Authors:  So-Ichi Suenobu; Kensuke Akiyoshi; Seigo Korematsu; Masahisa Takuma; Hiromu Mori; Tatsuro Izumi
Journal:  Int J Hematol       Date:  2008-01-29       Impact factor: 2.490

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.